Update on pharmacogenetics in epilepsy: a brief review

被引：57
作者：
Szoeke, CEI [1 ]
Newton, M
Wood, JM
Goldstein, D
Berkovic, SF
OBrien, TJ
Sheffield, LJ
机构：
[1] Univ Melbourne, Dept Med, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia
[3] Austin Hlth, Dept Neurol, Melbourne, Vic, Australia
[4] Mental Hlth Res Inst, Dept Pharmacogenom, Melbourne, Vic, Australia
[5] UCL, London, England
[6] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia
来源：
LANCET NEUROLOGY | 2006年 / 5卷 / 02期
关键词：
D O I：
10.1016/S1474-4422(06)70352-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Recent developments in the pharmacogenetics of antiepileptic drugs provide new prospects for predicting the efficacy of treatment and potential side-effects. Epilepsy is a common, serious, and treatable neurological disorder, yet current treatment is limited by high rates of adverse drug reactions and lack of complete seizure control in a significant proportion of patients. The disorder is especially suitable for pharmacogenetic investigation because treatment response can be quantified and side-effects can be assessed with validated measures. Additionally, there is substantial knowledge of the pharmacodynamics and kinetics of antiepileptic drugs, and some candidate genes implicated in the disorder have been identified. However, recent studies of the association of particular genes and their genetic variants with seizure control and adverse drug reactions have not provided unifying conclusions. This article reviews the published work and summarises the state of research in this area. Future directions for research and the application of this technology to the clinical practice of individualising treatment for epilepsy are discussed.
引用
收藏
页码：189 / 196
页数：8
相关论文
共 101 条
  • [41] KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209
  • [42] Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons
    Kanai, H
    Sawa, A
    Chen, RW
    Leeds, P
    Chuang, DM
    [J]. PHARMACOGENOMICS JOURNAL, 2004, 4 (05) : 336 - 344
  • [43] ABC drug transporters:: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2
    Kerb, R
    Hoffmeyer, S
    Brinkmann, U
    [J]. PHARMACOGENOMICS, 2001, 2 (01) : 51 - 64
  • [44] Metabolism and excretion of mood stabilizers and new anticonvulsants
    Ketter, TA
    Frye, MA
    Corá-Locatelli, G
    Kimbrell, TA
    Post, RM
    [J]. CELLULAR AND MOLECULAR NEUROBIOLOGY, 1999, 19 (04) : 511 - 532
  • [45] Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
    Kidd, RS
    Straughn, AB
    Meyer, MC
    Blaisdell, J
    Goldstein, JA
    Dalton, JT
    [J]. PHARMACOGENETICS, 1999, 9 (01): : 71 - 80
  • [46] MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences
    Kim, RB
    [J]. PHARMACOGENETICS, 2002, 12 (06): : 425 - 427
  • [47] Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
    Kuehl, P
    Zhang, J
    Lin, Y
    Lamba, J
    Assem, M
    Schuetz, J
    Watkins, PB
    Daly, A
    Wrighton, SA
    Hall, SD
    Maurel, P
    Relling, M
    Brimer, C
    Yasuda, K
    Venkataramanan, R
    Strom, S
    Thummel, K
    Boguski, MS
    Schuetz, E
    [J]. NATURE GENETICS, 2001, 27 (04) : 383 - 391
  • [48] Epilepsy after the first drug fails: substitution or add-on?
    Kwan, P
    Brodie, MJ
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2000, 9 (07): : 464 - 468
  • [49] Potential role of drug transporters in the pathogenesis of medically intractable epilepsy
    Kwan, P
    Brodie, TJ
    [J]. EPILEPSIA, 2005, 46 (02) : 224 - 235
  • [50] Early identification of refractory epilepsy.
    Kwan, P
    Brodie, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (05) : 314 - 319
12345678910